New Delhi: Zydus Lifesciences Ltd on Thursday said it has received tentative approval from the US health regulatory agency for its generic version of cancer treatment drug Ibrutinib tablets.
The Ibrutinib tablets will be produced at Zydus Lifesciences Ltd SEZ, Ahmedabad, it added.
The company said Ibrutinib is indicated for the treatment of adult patients with different types of blood cancers, Chronic lymphocytic leukaemia (CLL)/Small lymphocytic lymphoma (SLL), and Waldenstrom's macroglobulinemia (WM).
Citing IQVIA MAT May 2025, Zydus said Ibrutinib tablets had annual sales of USD 2148.9 million in the US.
Thane Tragedy: Three Sisters Die Of Suspected Food Poisoning In Shahapur, Police Launch Probe
.jpg)
Maharashtra Draft Housing Policy 2025 Pushes Transit Homes On Salt Pan, Port Trust Land To Fast-Track Slum Redevelopment
'Hinjewadi IT Park Moving To Bengaluru, Hyderabad': Ajit Pawar’s Outburst Sparks Political Firestorm
Mumbai-Pune Expressway Accident: One Woman Dead, Over 18 Injured After Truck With Failed Brakes Rams 25 Vehicles
(Except for the headline, this article has not been edited by FPJ's editorial team and is auto-generated from an agency feed.)
